Valuation: ICAD

Market Cap 106M 92.71M 85.34M 79.52M 150M 10.04B 153M 1.03B 398M 4.93B 396M 388M 17.15B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 77.92M 71.72M 66.83M 126M 8.44B 129M 863M 334M 4.14B 333M 326M 14.41B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
1 year 3.68
Extreme 3.68
3.99
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
17.3
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 09/03/2023
Director of Finance/CFO 54 16/07/2025
Corporate Secretary - 16/07/2025
Date Insider Type Main position Quantity % Market Cap.
16/07/25Issuer sale

Director

246,115 0.9273%
16/07/25Issuer sale

Director

87,408 0.3293%
16/07/25Issuer sale

Chief Financial Officer

158,488 0.5972%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%+4.03%+137.42% 106M
+2.47%+4.38%+23.41%+1.69% 191B
+4.38%+4.60%-22.67%+24.41% 143B
+1.73%+2.10%-2.58%-16.70% 137B
+5.18%+1.72%-56.61%-16.03% 64B
+1.89%+4.55%+21.79%+2.52% 52.97B
+1.39%+1.63%-26.28%-31.02% 43.82B
+0.07%-1.42%+10.72%+11.96% 37.67B
-0.57%-0.06%+7.03%+42.26% 37.13B
+0.93%+0.86%-13.95%-18.83% 29.5B
Average +2.10%+2.13%-5.51%+13.77% 73.56B
Weighted average by Cap. +2.50%+3.37%-3.38%+1.01%

Financials

2023 2024
Net sales 17.32M 15.21M 14M 13.04M 24.6M 1.65B 25.1M 168M 65.22M 808M 65.02M 63.62M 2.81B 19.61M 17.22M 15.85M 14.77M 27.85M 1.86B 28.41M 191M 73.85M 915M 73.62M 72.03M 3.18B
Net income -4.85M -4.26M -3.92M -3.65M -6.88M -461M -7.02M -47.11M -18.25M -226M -18.2M -17.81M -787M -5.62M -4.93M -4.54M -4.23M -7.98M -534M -8.14M -54.59M -21.15M -262M -21.09M -20.63M -912M
Net Debt -21.21M -18.62M -17.14M -15.97M -30.12M -2.02B -30.73M -206M -79.88M -990M -79.63M -77.91M -3.44B -16.84M -14.79M -13.61M -12.68M -23.92M -1.6B -24.41M -164M -63.44M -786M -63.24M -61.88M -2.74B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock